Biotechnology Company PhiTech Receives Investment

Biotechnology company PhiTech received investment from Arya GSYF. According to the information obtained, Arya GSYF made its seventh investment in PhiTech, a health biotechnology startup focusing on genome technologies, with 250 thousand dollars. What do we know about Arya GCIF? It was established in partnership with Arya Women Investment Platform and Maxis.

Also See: HockeyStack Receives $2.7 Million Investment

PhiTech

What do we know about PhiTech? It was founded by Prof. Dr. Saliha Durmuş, Prof. Dr. Tunahan Çakır and Prof. Dr. Erdoğan Sevilgen. We should mention that it has developed an artificial intelligence-supported clinical decision support system that processes DNA and RNA sequence data. In particular, the startup aims at early and accurate diagnosis against diagnostic processes that can take years in rare genetic diseases. It is preparing to start offering bioinformatics (data processing) solutions that carry the diagnostic power of RNA to clinical practice in early 2024 through its platform called Genomics & More.

What shaped Arya GCF's decision to invest in PhiTech? The team of highly competent scientists with complementary specialisations led by Saliha Durmuş and deep technological R&D studies that develop innovative diagnostic solutions. In the 21st century, it is known that beyond DNA-based technologies that transform medicine, innovative RNA-based approaches will now play an active role in diagnosis and treatment. It aims to make significant contributions to the field globally with the bioinformatics solutions developed in this field.